Cuiying Xu

Guangzhou Virotech Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Virotech") was registered and established in January 2015 at the Guangzhou International Business Incubator by Professor Yan Guangmei's original team from Sun Yat sen University. It is committed to the development of innovative oncolytic virus drugs in First in Class and Best in Class, and strives to create oncolytic virus technology for root cancer. Since its establishment, Weilongte has won multiple honors such as the Top 50 Most Innovative Chinese Biopharmaceutical Enterprises, Guangdong Province's Specialized and Innovative Small and Medium sized Enterprises, and Guangzhou's Future Unicorn Enterprise. It is one of the top biopharmaceutical enterprises in its segmented industry.
Weilongte has established the globally original and pioneering leading technology oncolytic virus M1, which has three major advantages: "precision treatment", "intravenous injection", and "freeze-drying preparation". This technology has applied for 81 patents, covering 53 countries and regions, of which 51 have been authorized. With its remarkable progressiveness and leadership, Verizon's core technology patents were selected into the 23rd "Silver Award of China Patent Award", and several patents were selected into the "Top 100 Patents of Guangzhou Development Zone".